Drug Transporters in Drug Disposition, Drug Interactions, and Drug Resistance

Drug Metabolism in Drug Design and Development: Basic Concepts and Practice

Volumn , Issue , 2007, Pages 137-202

  Xia, Cindy Q ^a   Yang, Johnny J ^a   Balani, Suresh K ^a  

^a DMPK NCDS   (United States)

Author keywords

Blood brain barriers; Facilitative transporter and active transporter; Transporter related drug drug interactions

Indexed keywords

EID: 84889269970     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470191699.ch6     Document Type: Chapter

References (253)

1. Adachi Y, Kobayashi H, Kurumi Y, Shouji M, Kitano M, Yamamoto T. ATPdependent taurocholate transport by rat liver canalicular membrane vesicles. Hepatology (Philadelphia, PA, United States) 1991;14:655-659.
2. Adachi Y, Suzuki H, Schinkel AH, Sugiyama Y. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol Pharmacol 2005;67:923-928.
3. Allen JD, Van Loevezijn A, Lakhai JM, Van der Valk M, Van Tellingen O, Reid G, Schellens JHM, Koomen G-J, Schinkel AH. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002;1:417-425.
4. Allen JD, van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 2003;63:1339-1344.
5. Ameyaw M-M, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, Thornton N, Folayan GO, Githang'a J, Indalo A, Ofori-Adjei D, Price-Evans DA, Mc Leod HL. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001;11:217-221.
6. Amsden G, Nafziger A, Foulds G, Cabelus L. A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. J Clin Pharmacol 2000;40:1522-1527.
7. Andrejak M, Hary L, Andrejak M, Lesbre J. Diltiazem increases steady state digoxin serum levels in patients with cardiac disease. J Clin Pharmacol 1987;27:967-970.
8. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993;65:410-413.
9. Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 2001;1:382-386. DOI:10.1034/j.1600-6143.2001.10415.x.
10. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998;64:369-377.
11. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA, Anastasi J, Powell BL, Kolitz JE, Schiffer CA, Bloomfield CD, Larson RA. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: cancer and leukemia group B study 9720. Blood 2002;100:1224-1232.
12. Balani SK, Miwa GT, Gan L-S, Wu J-T, Lee FW. Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. Curr Top Med Chem 2005;5:1033-1038.
13. Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, Sinko PJ. Direct evidence for peptide transporter (Pep T1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun 1998;250:246-251.
14. Batrakova EV, Li S, Li Y, Alakhov VY, Kabanov AV. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 2004;21:2226-2233.
15. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, Funck-Brentano C. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001;70:311-316.
16. Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Nat Cancer Inst 1995;87:1593-1602.
17. Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: Implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003;4:393-398.
18. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2004;277:3-9.
19. Berg SL, Tolcher A, O'Shaughnessy JA, Denicoff AM, Noone M, Ognibene FP, Cowan KH, Balis FM. Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J Clin Oncol 1995;13:2039-2042.
20. Bogman K, Erne-Brand F, Alsenz J, Drewe J. The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins. J Pharm Sci 2003;92:1250-1261.
21. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM. Phase I study of etoposide with SDZ PSC 833 as a modulator ofmultidrug resistance in patients with cancer. J Clin Oncol 1996;14:610-618.
22. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-592.
23. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Nat Cancer Inst 2000;92:1295-1302.
24. Boulton DW, De Vane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002;71:163-169.
25. Boyd R, Stern R, Stewart B, Wu X, Reyner E, Zegarac E, Randinitis E, Whitfield L. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000;40:91-98.
26. Boyer JL, Meier PJ. Characterizing mechanisms of hepatic bile acid transport utilizing isolated membrane vesicles. Methods Enzymol 1990;192:517-533.
27. Breedveld P, Pluim D, Cipriani G, Wielinga P, Van Tellingen O, Schinkel AH, Schellens JHM. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005;65:2577-2582.
28. Brown GR. Cephalosporin-probenecid drug interactions. Clin Pharmacokinet 1993; 24:289-300.
29. Buechler M, Koenig J, Brom M, Kartenbeck J, Spring H, Horie T, Keppler D. c DNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, c Mrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 1996;271:15091-15098.
30. Buss N, Snell P, Bock J, Hsu A, Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 2001;52:255-264.
31. Calvo MV, Martin-Suarez A, Martin Luengo C, Avila C, Cascon M, Dominguez-Gil Hurle A. Interaction between digoxin and propafenone. Ther Drug Monit 1989;11:10-15.
32. Campbell SD, de Morais SM, Xu JJ. Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem Biol Interact 2004;150:179-187.
33. Center MS, Zhu Q, Sun H. Mutagenesis of the putative nucleotide-binding domains of the multidrug resistance associated protein (MRP). Analysis of the effect of these mutations on MRP mediated drug resistance and transport. Cytotechnology 1998;27:61-69.
34. Chang T, Benet LZ, Hebert MF. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 1996;59:297-303.
35. Chang X-B, Hou Y-X, Riordan JR. Stimulation of ATPase activity of purified multidrug resistance-associated protein by nucleoside diphosphates. J Biol Chem 1998;273:23844-23848.
36. Chen C, Liu X, Smith BJ. Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. Curr Drug Metab 2003a;4:272-291.
37. Chen C, Scott D, Hanson E, Franco J, Berryman E, Volberg M, Liu X. Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using eisai hyperbilirubinemic rats. Pharm Res 2003b;20:31-37.
38. Christensen H, Asberg A, Holmboe AB, Berg KJ. Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. Eur J Clin Pharmacol 2002;58:515-520.
39. Cohen A, Ullman B, Martin DW Jr. Characterization of a mutant mouse lymphoma cell with deficient transport of purine and pyrimidine nucleosides. J Biol Chem 1979;254:112-116.
40. Collnot EM, Baldes C, Wempe MF, Hyatt J, Navarro L, Edgar KJ, Schaefer UF, Lehr CM. Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Control Release 2006;111:35-40.
41. Cui Y, Konig J, Leier I, Buchholz U, Keppler D. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001;276:9626-9630.
42. Davit B, Reynolds K, Yuan R, Ajayi F, Conner D, Fadiran E, Gillespie B, Sahajwalla C, Huang S-M, Lesko LJ. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol 1999;39:899-910.
43. Dean M, Fojo T, Bates S. Tumor stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284.
44. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Nat Acad Sci USA 1998;95:15665-15670.
45. Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 2005;77:170-177.
46. Druekes P, Schinzel R, Palm D. Photometric microtiter assay of inorganic phosphate in the presence of acid-labile organic phosphates. Anal Biochem 1995;230:173-177.
47. Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz JD, Watkins P. 60, 70-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999;65:237-244.
48. Elferink RPJO, De Haan J, Lambert KJ, Hagey LR, Hofmann AF, Jansen PLM. Selective hepatobiliary transport of nordeoxycholate side chain conjugates in mutant rats with a canalicular transport defect. Hepatology (Philadelphia, PA, United States) 1989;9:861-865.
49. Endres CJ, Hsiao P, Chung FS, Unadkat JD. The role of transporters in drug interactions. Eur J Pharm Sci 2006;27:501-517.
50. Fedeli L, Colozza M, Boschetti E, Sabalich I, Aristei C, Guerciolini R, Del Favero A, Rossetti R, Tonato M, Rambotti P, Davis S. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 1989;64:1805-1811.
51. Fenster PE, Hager WD, Goodman MM. Digoxin-quinidine-spironolactone interaction. Clin Pharmacol Ther 1984;36:70-73.
52. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hebert MF. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997;62:41-49.
53. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Nat Acad Sci USA 1987;84:265-269.
54. Forman B, Dussault I, Synold TW. Methods for altering SXR activation using peptide mimetic HIV proteaseinhibitor SXR ligands to reduce drug resistance and drug clearance; US. Pat. Appl. Publ. 32 pp., Cont.-in-part of U. S. Ser. No. 815,300. USA,2002.
55. Fotoohi AK, Lindqvist M, Peterson C, Albertioni F. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun 2006;343:208-215.
56. Garrigues A, Nugier J, Orlowski S, Ezan E. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal Biochem 2002;305:106-114.
57. Gati WP, Paterson ARP, Belch AR, Chlumecky V, Larratt LM, Mant MJ, Turner AR. Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (ara C). Leuk Lymphoma 1998;32:45-54.
58. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996;62:1559-1564.
59. Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J Bioenerg Biomembr 2001;33:453-458.
60. Gottesman MM, Pastan I, Ueda K. Methods of inducing multidrug resistance in mammalian cells using vectors carrying the human MDR1 gene; U. S. 11 pp., (United States Dept. of Health and Human Services, USA) 1999.
61. Gramatte T, Oertel R. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 1999;66:239-245.
62. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. [erratum appears in J Clin Invest 2002 Aug;110(4):571]. J Clin Invest 1999a;104:147-153.
63. Greiner B, Eichelbaum M, Fritz P, Kreichgauer H-P, von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999b;104:147-153.
64. Grem JL. Biochemical modulation of fluorouracil by dipyridamole: preclinical and clinical experience. Semin Oncol 1992;19:56-65.
65. Grub S, Bryson H, Goggin T, Ludin E, Jorga K. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 2001;57:115-121.
66. Gupta SK, Bakran A, Johnson RW, Rowland M. Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989;27:475-481.
67. Gupta S, Banfield C, Kantesaria B, Marino M, Clement R, Affrime M, Batra V. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther 2001;23:451-466.
68. Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J. Distribution of breast cancer resistance protein (BCRP/ABCG2) m RNA expression along the human GI tract. Biochem Pharmacol 2005;70:695-699.
69. Haimeur A, Conseil G, Deeley RG, Cole SPC. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 2004;5:21-53.
70. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther (St. Louis, MO, United States) 2001;69:114-121.
71. Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999;39:91-96.
72. Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. Ann Pharmacother 1999;33:680-682.
73. Hedman A, Angelin B, Arvidsson A, Dahlqvist R, Nilsson B. Interactions in the renal biliary elimination of digoxin: stereoselective difference between quinine and quinidine. Clin Pharmacol Ther (St. Louis, MO. United States) 1990;47:20-26.
74. Hedman A, Angelin B, Arvidsson A, Beck O, Dahlqvist R, Nilsson B, Olsson M, Schenck-Gustafsson K. Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 1991;49:256-262.
75. Hindmarch I. CNS effects of antihistamines: is there a third generation of non-sedative drugs? Clin Exp Allergy Rev 2002;2:26-31.
76. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004;311:139-146.
77. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 2005;68:800-807.
78. Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000;11:383-393.
79. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78:260-277.
80. Hoffman J. Murine erythroleukemia cells resistant to periodate-oxidized adenosine have lowered levels of nucleoside transporter. Adv Exp Med Biol 1991;309A: 443-446.
81. Hoffmaster KA, Turncliff RZ, Le Cluyse EL, Kim RB, Meier PJ, Brouwer KLR. P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res 2004a;21:1294-1302.
82. Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KLR. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J Pharmacol Exp Ther 2004b;311:1203-1210.
83. Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993;266:1620-1625.
84. Horikawa M, Kato Y, Tyson CA, Sugiyama Y. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet 2002;17:23-33.
85. Huang M-J, Kua K-E, Teng H-C, Tang K-S, Weng H-W, Huang C-S. Risk factors for severe hyperbilirubinemia in neonates. Pediatr Res 2004;56:682-689.
86. Ieiri I, Suzuki H, Kimura M, Takane H, Nishizato Y, Irie S, Urae A, Kawabata K, Higuchi S, Otsubo K, Sugiyama Y. Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. Hepatology Res 2004;30:91-95.
87. Ishizuka H, Konno K, Shiina T, Naganuma H, Nishimura K, Ito K, Suzuki H, Sugiyama Y. Species differences in the transport activity for organic anions across the bile canalicular membrane. J Pharmacol Exp Ther 1999;290:1324-1330.
88. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997;19:609-613.
89. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338-345.
90. Johne A, Schmider J, Brockmoller J, Stadelmann AM, Stormer E, Bauer S, Scholler G, Langheinrich M, Roots I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002;22:46-54.
91. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JHM, Schinkel AH. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Nat Cancer Inst 2000;92:1651-1656.
92. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, Schinkel AH. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 2005;11:127-129.
93. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta Biomembr 1976; 455:152-162.
94. Kamisako T, Kobayashi Y, Takeuchi K, Ishihara T, Higuchi K, Tanaka Y, Gabazza EC, Adachi Y. Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance. J Gastroenterol 2000;35:659-664.
95. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther (St. Louis) 1998;64:177-182.
96. Kaplan B, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998;63:48-53.
97. Kaukonen K-M, Olkkola KT, Neuvonen PJ. Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther (St. Louis) 1997;62:510-517.
98. Kemp DC, Zamek-Gliszczynski MJ, Brouwer KLR. Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol Sci 2005;83:207-214.
99. Keppler D, Jedlitschky G, Leier I. Transport function and substrate specificity of multidrug resistance protein. Methods Enzymol 1998;292:607-616.
100. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett (Amsterdam, Netherlands) 2006;234:4-33.
101. Kerr DJ, Graham J, Cummings J, Morrison JG, Thompson GG, Brodie MJ, Kaye SB. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986;18:239-242.
102. Kilic T., Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, Buchdunger E., Black PM, Stiles CD. Intracranial inhibition of platelet-derived growth factormediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000;60:5143-5150.
103. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998;46:49-53.
104. Kleinbloesem CH, van Brummelen P, Hillers J, Moolenaar AJ, Breimer DD. Interaction between digoxin and nifedipine at steady state in patients with atrial fibrillation. Ther Drug Monit 1985;7:372-376.
105. Kong W, Engel K, Wang J. Mammalian nucleoside transporters. Curr Drug Metab 2004;5:63-84.
106. Kovarik JM, Purba HS, Pongowski M, Gerbeau C, Humbert H, Mueller EA. Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. Pharmacotherapy 1998;18:1230-1236.
107. Kovarik JM, Rigaudy L, Guerret M, Gerbeau C, Rost KL. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin. Clin Pharmacol Ther 1999;66:391-400.
108. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, Schellens JH. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 2002;20:2943-2950.
109. Kullak-Ublick GA. Drug-induced cholestatic liver disease. Molecular Pathogenesis of Cholestasis. Landes Bioscience, Georgetown, Tx. 2004;256-265.
110. Kurisu H, Kamisaka K, Koyo T, Yamasuge S, Igarashi H, Maezawa H, Uesugi T, Tagaya O. Organic anion transport study in mutant rats with autosomal recessive conjugated hyperbilirubinemia. Life Sci 1991;49:1003-1011.
111. Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 2005;46:224-235.
112. Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CEAC, Keohane CA, Ly VT, Strauss JR, Wang RW, Wang Z, Pippert TR, Umbenhauer DR. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 1999;27:581-587.
113. Lai Y, Tse C-M, Unadkat JD. Mitochondrial expression of the human equilibrative nucleoside transporter 1 (h ENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem 2004;279:4490-4497.
114. Lankas GR, Cartwright ME, Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 1997;143:357-365.
115. Lau YY, Wu C-Y, Okochi H, Benet LZ. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther 2004;308:1040-1045.
116. Lau YY, Okochi H, Huang Y, Benet LZ. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther 2006;316:762-771.
117. Lee E-W, Lai Y, Zhang H, Unadkat JD. Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (h ENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine. J Biol Chem 2006.
118. Leis J, Stepan D, Curtin P, Ford J, Peng B, Schubach S, Druker B, Maziarz R. Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia and Lymphoma 2004; Treated with Imatinib (STI-571). Leukemia-Lymphoma 2004;45(4):695-698.
119. Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ, Stewart CF. Gefitinib modulates the function of multiple ATPbinding cassette transporters in vivo. Cancer Res 2006;66:4802-4807.
120. Lessem J, Bellinetto A. Interaction between digoxin and the calcium antagonists nicardipine and tiapamil. Clin Ther 1983;5:595-602.
121. Li Q, Sai Y, Kato Y, Tamai I, Tsuji A. Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines. Pharm Res 2003;20:1119-1124.
122. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-Co A reductase inhibitors. Clin Pharmacol Ther (St. Louis) 1998;64:477-483.
123. Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol 2004;58:56-60.
124. Lindell M, Karlsson MO, Lennernas H, Pahlman L, Lang MA. Variable expression of CYP and Pgp genes in the human small intestine. Eur J Clin Invest 2003;33:493-499.
125. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, Shurafa M, Appelbaum FR. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001;98:3212-3220.
126. Litman T, Zeuthen T, Skovsgaard T, Stein WD. Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta (BBA) -Mol Basis of Disease 1997;1361:169-176.
127. Liu L, Pang KS. The roles of transporters and enzymes in hepatic drug processing. Drug Metab Dispos 2005;33:1-9.
128. Liu X, Lecluyse EL, Brouwer KR, Lightfoot RM, Lee JI, Brouwer KLR. Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 1999;289:1592-1599.
129. Loescher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol (Amsterdam, Netherlands) 2005;76:22-76.
130. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. Role of intestinal Pglycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-260.
131. Lu C, Miwa GT, Prakash SR, Gan L-S, Balani SK. A novel model for the prediction of drug-drug interactions in humans based on in vitro cyp phenotypic data. Drug Metab Dispos 2007;35:79-85.
132. Lum B, Kaubisch S, Yahanda A, Adler K, Jew L, Ehsan M, Brophy N, Halsey J, Gosland M, Sikic B. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992;10:1635-1642.
133. Mackey JR, Baldwin SA, Young JD, Cass CE. Nucleoside transport and its significance for anticancer drug resistance. Drug Resis Updat 1998a;1:310-324.
134. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998b;58:4349-4357.
135. Mai I, Kruger H, Budde K, Johne A, Brockmoller J, Neumayer HH, Roots I. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000;38:500-502.
136. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, Schellens JH. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 2001a;84:42-47.
137. Malingre MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW, Schot ME, Schellens JHM. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001b;19:1160-1166.
138. Maxwell DL, Gilmour-White SK, Hall MR. Digoxin toxicity due to interaction of digoxin with erythromycin. BMJ 1989;298:572.
139. Meerum Terwogt JM, Malingre MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ, van Tellingen O, Swart M, Schellens JHM. Coadministration of oral cyclosporin a enables oral therapy with paclitaxel. Clin Cancer Res 1999;5:3379-3384.
140. Meier PJ, Boyer JL. Preparation of basolateral (sinusoidal) and canalicular plasma membrane vesicles for the study of hepatic transport processes. Methods Enzymol 1990;192:534-545.
141. Meier PJ, St. Meier-Abt A, Barrett C, Boyer JL. Mechanisms of taurocholate transport in canalicular and basolateral rat liver plasma membrane vesicles. Evidence for an electrogenic canalicular organic anion carrier. J Biol Chem 1984;259:10614-10622.
142. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 2005;67:1758-1764.
143. Mills E, Wu P, Johnston BC, Gallicano K, Clarke M, Guyatt G. Natural health product-drug interactions: a systematic review of clinical trials. Ther Drug Monit 2005;27:549-557.
144. Millward MJ, Webster LK, Rischin D, Stokes KH, Toner GC, Bishop JF, Olver IN, Linahan BM, Linsenmeyer ME, Woodcock DM. Phase I trial of cremophor EL with bolus doxorubicin. Clin Cancer Res 1998;4:2321-2329.
145. Mizuno N, Suzuki M, Kusuhara H, Suzuki H, Takeuchi K, Niwa T, Jonker JW, Sugiyama Y. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab Dispos 2004;32:898-901.
146. Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced nonsmall- cell lung cancer. Cancer Chemother Pharmacol 2003;51:403-406.
147. Mouly SJ, Paine MF, Watkins PB. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. J Pharmacol Exp Ther 2004;308:941-948.
148. Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000;67:267-274.
149. Muck W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde K, Roots I, Neumayer HH, Kuhlmann J. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 1999;65:251-261.
150. Mulato AS, Ho ES, Cihlar T. Nonsteroidal anti-inflammatory drugs efficiently reduce the transport and cytotoxicity of adefovir mediated by the human renal organic anion transporter 1. J Pharmacol Exp Ther 2000;295:10-15.
151. Muller M, Jansen PLM. Molecular aspects of hepatobiliary transport. Am J Physiol 1997;272:G1285-G1303.
152. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther (St. Louis) 1998;63:332-341.
153. Neville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, Mc Guffey L, Mc Cully C, Berg SL, Blaney SM. Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates. Clin Cancer Res 2004;10:25257-2529.
154. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivisto KT. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther (St. Louis, MO, United States) 2001;69:400-406.
155. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivisto KT. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C. SLCO1B1). Pharmacogenetics 2004;14:429-440.
156. Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 2005;59:602-604.
157. Niemi M, Kivisto KT, Diczfalusy U, Bodin K, Bertilsson L, Fromm MF, Eichelbaum M. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenet Genomics 2006a;16:565-568.
158. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006b;80:356-366.
159. Ninomiya M, Ito K, Horie T. Functional analysis of dog multidrug resistanceassociated protein 2 (MRP2) in comparison with rat MRP2. Drug Metab Dispos 2005;33:225-232.
160. Ocheltree SM, Shen H, Hu Y, Keep RF, Smith DE. Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild type and PEPT2 knockout mice. J Pharm Exp Ther 2005;315:240-247.
161. Oerlemans R, van der Heijden J, Vink J, Dijkmans BAC, Kaspers GJL, Lems WF, Scheffer GL, Ifergan I, Scheper RJ, Cloos J, Assaraf YG, Jansen G. Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistanceassociated protein 1 and provokes high levels of cross-resistance to glucocorticoids. Arthritis Rheum 2006;54:557-568.
162. Ogihara T, Kamiya M, Ozawa M, Fujita T, Yamamoto A, Yamashita S, Ohnishi S, Isomura Y. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine. Drug Metab Pharmacokinet 2006;21:238-244.
163. Ohmori S, Kuriya S, Uesugi T, Horie T, Sagami F, Mikami T, Kawaguchi A, Rikihisa T, Kanakubo Y. Decrease in the specific forms of cytochrome P-450 in liver microsomes of a mutant strain of rat with hyperbilirubinuria. Res Commun Chem Pathol Pharmacol 1991;72:243-253.
164. Okamura N, Hirai M, Tanigawara Y, Tanaka K, Yasuhara M, Ueda K, Komano T, Hori R. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. J Pharmacol Exp Ther 1993;266:1614-1619.
165. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 2001;285:111-117.
166. Ozvegy C, Varadi A, Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J Biol Chem 2002;277:47980-47990.
167. Paine MF, Wagner DA, Hoffmaster KA, Watkins PB. Cytochrome P450 3A4 and Pglycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Clin Pharmacol Ther (St. Louis, MO, United States) 2002;72:524-535.
168. Paul AJ, Tranquilli WJ, Seward RL, Todd KS, Jr, Di Pietro JA. Clinical observations in collies given ivermectin orally. Am J Vet Res 1987;48:684-685.
169. Pedersen KE, Christiansen BD, Klitgaard NA, Nielsen-Kudsk F. Effect of quinidine on digoxin bioavailability. Eur J Clin Pharmacol 1983;24:41-47.
170. Perloff MD, Von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001;134:1601-1608.
171. Pfeifer H, Wassmann B, Hofmann WK, Komor M, Scheuring U, Brueck P, Binckebanck A, Schleyer E, Goekbuget N, Wolff T, Luebbert M, Leimer L, Gschaidmeier H, Hoelzer D, Ottmann OG. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 2003;9:4674-4681.
172. Pichler A, Zelcer N, Prior JL, Kuil AJ, Piwnica-Worms D. In vivo RNA interferencemediated ablation of MDR1 P-Glycoprotein. Clin Cancer Res 2005;11:4487-4494.
173. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000;355:547-548.
174. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34: 234-238.
175. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001;299:620-628, Promega. Available at http://www.promega.com/tbs/tb341/tb341.pdf.
176. Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Webster LO, Barnaby RJ, Vitulli G, Bertolotti L, Read KD, Serabjit-Singh CJ. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters. Drug Metab Dispos 2004;32:722-726.
177. Ramachandra M, Ambudkar SV, Gottesman MM, Pastan I, Hrycyna CA. Functional characterization of a glycine 185-to-valine substitution in human P-glycoprotein by using a vaccinia-based transient expression system. Mol Biol Cell 1996;7:1485-1498.
178. Rao US. Mutation of glycine 185 to valine alters the ATPase function of the human Pglycoprotein expressed in Sf9 cells. J Biol Chem 1995;270:6686-6690.
179. Robinson K, Johnston A, Walker S, Mulrow JP, Mc Kenna WJ, Holt DW. The digoxin-amiodarone interaction. Cardiovasc Drugs Ther 1989;3:25-28.
180. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 1994;74:834-841.
181. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000a;68:231-237.
182. Sadeque AJM, Wandel C, He H, Shah S, Wood AJJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther (St. Louis) 2000b;68:231-237.
183. Sadler BM, Gillotin C, Lou Y, Eron JJ, Lang W, Haubrich R, Stein DS. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. Antimicrob Agents Chemother 2001;45:3663-3668.
184. Sarkadi B, Price EM, Boucher RC, German UA, Scarborough GA. Expression of the human multidrug resistance c DNA insect cells generates a high activity drugstimulated membrane ATPase. J Biol Chem 1992;267:4854-4858.
185. Sarkadi B, Homolya L, Hollo Z. Assay and reagent kit for evaluation of multi-drug resistance in cells; U. S. pp 17 pp., Cont.-in-part of U. S. 15,872,014, (Solvo Biotechnology, Hung). 2001.
186. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther (New York, NY, United States) 2005;77:503-514.
187. Satoh K, Shirabe S, Eguchi K, Yamauchi A, Kataoka Y, Niwa M, Nishida N, Katamine S. Toxicity of quinacrine can be reduced by co-administration of P-Glycoprotein inhibitor in sporadic creutzfeldt-jakob disease. Cell Mol Neurobiol 2004;24:873-875.
188. Scarborough GA. Drug-stimulated ATPase activity of the human P-glycoprotein. J Bioenerg Biomembr 1995;27:37-41.
189. Schwarz UI, Gramatte T, Krappweis J, Berndt A, Oertel R, von Richter O, Kirch W. Unexpected effect of verapamil on oral bioavailability of the [beta]-blocker talinolol in humans. Clin Pharmacol Ther 1999;65:283-290.
190. Schwarz UI, Gramatte T, Krappweis J, Oertel R, Kirch W. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 2000;38:161-167.
191. Senior AE, al-Shawi MK, Urbatsch IL. ATP hydrolysis by multidrug resistance protein from Chinese hamster ovary cells. J Bioenerg Biomembr 1995;27:31-36.
192. Shapiro AB, Corder AB, Ling V. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur J Biochem 1997;250:115-121.
193. Shapiro AB, Fox K, Lam P, Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 1999;259:841-850.
194. Shepard RL, Cao J, Starling JJ, Dantzig AH. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. Int J Cancer 2003;103: 121-125.
195. Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, Sugiyama Y. Function of uptake transporters for taurocholate and estradiol 17b-D-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet 2003;18:33-41.
196. Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Ann Rev Pharmacol Toxicol 2005;45:689-723.
197. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006;27:425-446.
198. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-Co A) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112:71-105.
199. Siedlik P, Olson S, Yang B, Stern R. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 1999;39:501-504.
200. Siegmund W, Ludwig K, Engel G, Zschiesche M, Franke G, Hoffmann A, Terhaag B, Weitschies W. Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets. J Pharm Sci 2003;92:604-610.
201. Sigel E. Use of Xenopus oocytes for the functional expression of plasma membrane proteins. J Membr Biol 1990;117:201-221.
202. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76:167-177.
203. Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000;59:301-321.
204. Sobrero AF, Handschumacher RE, Bertino JR. Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-20-deoxyuridine. Cancer Res 1985a;45:3161-3163.
205. Sobrero AF, Moir RD, Bertino JR, Handschumacher RE. Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-20- deoxyuridine in the HCT-8 human carcinoma line. Cancer Res 1985b;45:3155-3160.
206. Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn J-Y, Sadoun A, Pignon B, Berthou C, Maloisel F, Guyotat D., Casassus P, Ifrah N, Lamy Y, Audhuy B, Colombat P, Harousseau JL. Combination of Quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias a randomized multicenter study. Blood 1996;88:1198-1205.
207. Solary E, Drenou B, Campos L, De Cremoux P, Mugneret F, Moreau P, Lioure B, Falkenrodt A, Witz B, Bernard M, Hunault-Berger M, Delain M, Fernandes J, Mounier C, Guilhot F, Garnache F, Berthou C, Kara-Slimane F, Harousseau J-L. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 2003;102:1202-1210.
208. Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, Lokhorst H, van der Lelie J, Dohner H, Gerhartz H, Segeren CM, Willemze R, Lowenberg B. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone; in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 2001;115:895-902.
209. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, van Tellingen O, Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. PNAS 1997;94:2031-2035.
210. Sparreboom A, Planting AS, Jewell RC, van der Burg ME, van der Gaast A, de Bruijn P, Loos WJ, Nooter K, Chandler LH, Paul EM, Wissel PS, Verweij J. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. Anticancer Drugs 1999;10:719-728.
211. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003;6:71-84.
212. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med (New York, NY, United States) 2001;7:584-590.
213. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-234.
214. Tabas LB, Dantzig AH. A high-throughput assay for measurement of multidrug resistance protein-mediated transport of leukotriene C4 into membrane vesicles. Anal Biochem 2002;310:61-66.
215. Tahara H, Kusuhara H, Fuse E, Sugiyama Y. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 2005;33:963-968.
216. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T, Endou H. Characterization of methotrexate transport and its drug interactions with human organic anion transporter. J Pharmacol Exp Ther 2002;302: 666-671.
217. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Nat Acad Sci USA 1987;84:7735-7738.
218. Thoern M, Finnstroem N, Lundgren S, Rane A, Loeoef L. Cytochromes P450 and MDR1 m RNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 2005;60:54-60.
219. Tokui T, Nakai D, Nakagomi R, Yawo H, Abe T, Sugiyama Y. Pravastatin, an HMGCo A reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res 1999;16:904-908.
220. Tsuruoka S, Ioka T, Wakaumi M, Sakamoto K, Ookami H, Fujimura A. Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter. Clin Pharmacol Ther 2006;79:389-396.
221. van der Heijden J, de Jong MC, Dijkmans BAC, Lems WF, Oerlemans R, Kathmann I, Schalkwijk CG, Scheffer GI, Scheper RJ, Jansen G. Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFa. Ann Rheum Dis 2004a;63:138-143.
222. van der Heijden J, de Jong MC, Dijkmans BAC, Lems WF, Oerlemans R, Kathmann I, Scheffer GI, Scheper RJ, Assaraf YG, Jansen G. Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to nonrelated DMARDs. Ann Rheum Dis 2004b;63:131-137.
223. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000;6:2598-2603.
224. Velpandian T, Jasuja R, Bhardwaj RK, Jaiswal J, Gupta SK. Piperine in food: interference in the pharmacokinetics of phenytoin. Eur J Drug Metab Pharmacokine 2001;26:241-248.
225. Volk EL, Schneider E. Wild type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003;63:5538-5543.
226. Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui K. Effect of clarithromycin on renal excretion of digoxin: interaction with Pglycoprotein. Clin Pharmacol Ther 1998;64:123-128.
227. Wang E-J, Casciano CN, Clement RP, Johnson WW. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Dispos 2000;28:522-528.
228. Wang E-j, Casciano CN, Clement RP, Johnson WW. Fluorescent substrates of sister-Pglycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res 2003;20:537-544.
229. Wang Z, Hamman MA, Huang S-M, Lesko LJ, Hall SD. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (St. Louis, MO, United States) 2002;71:414-420.
230. Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A, Mahe B, Milpied N, Janvier M, Guerci A, Rochant H, Cordonnier C, Dreyfus F, Buzyn A, Hoang-Ngoc L, Stoppa AM, Gratecos N, Sadoun A, Stamatoulas A, Tilly H, Brice P, Maloisel F, Lioure B, Desablens B, Pignon B, Abgrall JP, Leporrier M, Dupriez B, Guyotat D, Lepelley P, Fenaux P. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 1998;102:1015-1024.
231. Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A, Milpied N, Janvier M, Guerci A, Rochant H, Cordonnier C, Dreyfus F, Veil A, Hoang-Ngoc L, Stoppa AM, Gratecos N, Sadoun A, Tilly H, Brice P, Lioure B, Desablens B, Pignon B, Abgrall JP, Leporrier M, Dupriez B, Guyotat D, Lepelley P, Fenaux P. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP): updated results of a randomized study. Adv Exp Med Biol 1999;457:35-46.
232. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, Miranda Pd, Smiley ML. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther (St. Louis) 1993;54:595-605.
233. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 2000a;68:6-12.
234. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein [see comment]. Clin Pharmacol Ther 2000b;68:6-12.
235. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B, Kroemer HK, Siegmund W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 2000c;68:345-355.
236. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, Kauffmann H-M, Schrenk D, Terhaag B, Kroemer HK, Siegmund W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 2000d;68:345-355.
237. Wiley JS, Jones SP, Sawyer WH, Paterson ARP. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 1982;69:479-489.
238. Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, Finch LR. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest 1985;75:632-642.
239. Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr. The CNS is a sanctuary for leukemic cells in mice receiving Imatinib mesylate for Bcr/Abl-induced leukemia. Blood 2003;101:5010-5013.
240. Wright AMP, Paterson ARP, Sowa B, Akabutu JJ, Grundy PE, Gati WP. Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients: significance of cellular nucleoside transporter content. Br J Haematol 2002;116:528-537.
241. Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/ absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11-23.
242. Xia CQ, Liu N, Miwa G, Gan L-S. Use of in vitro models to study interactions between the breast cancer resistant protein and its ligands. Drug Metab Rev 2004;36:53.
243. Xia CQ, Liu N, Yang D, Miwa G, Gan L-S. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos 2005a;33:637-643.
244. Xia CQ, Yang JJ, Gan L-S. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions. Expert Opin Drug Metab Toxicol 2005b;1:595-611.
245. Xia CQ, Xiao G, Liu N, Pimprale S, Fox L, Patten CJ, Crespi CL, Miwa G, Gan L-S. Comparison of species differences of P-Glycoproteins in beagle dog, rhesus monkey, and human using ATPase activity assays. Mol Pharm 2006;3:78-86.
246. Xu D, Kang H, Fisher M, Juliano RL. Strategies for inhibition of MDR1 gene expression. Mol Pharmacol 2004;66:268-275.
247. Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. Uptake is the rate-limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res 1996;13:1559-1564.
248. Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (c MOAT). Drug Metab Dispos 1997;25:1123-1129.
249. Yin JAL, Wheatley K, Rees JKH, Burnett AK. Comparison of \"sequential\" versus\ "standard\" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukemia (AML): results of the UK medical research council AML-R trial. Br J Haemat 2001;113:713-726.
250. Yu D. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 1999;39:1203-1211.
251. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 2006;3:55-61.
252. Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E. Effect of grapefruit juice on the pharmacokinetics of Losartan and its active metabolite E3174 in healthy volunteers. Ther Drug Monit 2001;23:369-373.
253. Zamek-Gliszczynski MJ, Hoffmaster KA, Tian X, Zhao R, Polli JW, Humphreys JE, Webster LO, Bridges AS, Kalvass JC, Brouwer KLR. Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and BCRP1. Drug Metab Dispos 2005;33:1158-1165.